Abstract library

8 results for "Zandee".
#1517 Additional Value for Urinary 5-Hydroxyindoleacetic Acid as Prognostic Marker in Neuroendocrine Tumors?
Introduction: 5-Hydroxyindoleacetic Acid (5-HIAA) is of value for diagnosis of NETs and correlates with severity of carcinoid syndrome. However its value for determining prognosis is uncertain, particularly in combination with other biomarkers
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Wouter Zandee
Keywords: prognosis 5-HIAA
#1807 Adherence to WHO2010 Guideline for Diagnosis of Neuroendocrine Carcinoma and Prognostic Significance
Introduction: Neuroendocrine carcinoma’s (NEC) are diagnosed by a combination of immunohistochemistry (IHC) and morphology according to the 2010 WHO guidelines.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Pathology, grading, staging
Presenting Author: Wouter Zandee
#2046 Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?
Introduction: A proportion of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) referred to NEN expert centers need a histopathological revision.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Elettra Merola
#2072 Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic Grade 3 Neuroendocrine Neoplasms: A Retrospective International Multicenter Study
Introduction: Gastroenteropancreatic (GEP) grade 3 neuroendocrine neoplasms (NEN G3) are rare, highly malignant neoplasms with poor prognosis and limited therapeutic options. Median survival following chemotherapy is only 10-12 months.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: MD, PhD Dorthe Skovgaard
#2092 Palliative Surgery in Advanced Small Intestinal Neuroendocrine Tumors
Introduction: Small intestinal neuroendocrine tumours (SI-NETs) are known to develop mesenteric metastasis and fibrosis. Since this can induce intestinal obstruction, edema and ischaemia, prophylactic palliative resection of the primary tumour and mesenteric mass is often recommended in case of advanced disease but the evidence is disputable.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Drs. Anela Blazevic
#2137 Evaluation of Multidisciplinary Tumor Board Decisions in the Management of Neuroendocrine Tumors: Impact of Expert Centers
Introduction: ENETS requires Centers of Excellence to discuss all new gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in a multidisciplinary tumor board (MDT) but the true value of the MDT has never been assessed
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Wouter Zandee
#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study
Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD, Ph.D. Francesca Spada
#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis
Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Julie Refardt